News
Hosted on MSN28d
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or deathA large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...
Type 2 diabetes is a long-term condition where the body struggles to manage sugar levels in the blood. Normally, doctors ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Researchers at Thomas Jefferson University have found a new way to help. Their study showed that using two diabetes ...
Half of the participants received a weekly injection of two milligrams of the drug exenatide, which is a GLP-1 receptor ...
Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...
Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...
The i Paper on MSN15d
Exenatide does not slow Parkinson’s disease progression compared to placeboThere was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and well-tolerated compared to placebo. Evidence Rating Level: 1 (Excellent) Study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results